Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group

被引：88

作者：

Sperr, W. R. ^{[1
]}

Wimazal, F. ^{[1
]}

Kundi, M. ^{[2
]}

Baumgartner, C. ^{[1
]}

Noesslinger, T. ^{[3
]}

Makrai, A. ^{[3
]}

Stauder, R. ^{[4
]}

Krieger, O. ^{[5
]}

Pfeilstoecker, M. ^{[1
,6
]}

Valent, P. ^{[1
,6
]}

机构：

[1] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, A-1090 Vienna, Austria

[2] Med Univ Vienna, Inst Environm Hlth, A-1090 Vienna, Austria

[3] Hanusch Hosp, Med Dept Hematol & Oncol 3, Vienna, Austria

[4] Med Univ Innsbruck, Dept Internal Med 5, Innsbruck, Austria

[5] Hosp Elisabethinen, Dept Internal Med 1, Linz, Austria

[6] Ludwig Boltzmann Cluster Oncol, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷 / 01期

关键词：

comorbidity; MDS; prognostication; survival; PRIMARY MYELODYSPLASTIC SYNDROMES; SCORING SYSTEM; ELDERLY-PATIENTS; PREDICTING SURVIVAL; CLASSIFICATION; PROPOSALS; DIAGNOSIS; CANCER; LEUKEMIA; IMPACT;

D O I：

10.1093/annonc/mdp258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients and methods: In the present study, the influence of comorbidity on survival and acute myeloid leukemia (AML) evolution was analyzed retrospectively in 419 patients with de novo myelodysplastic syndromes (MDS) (observation period: 1985-2007). The median age was 71 years (range 24-91 years). Two different scoring systems, the hematopoietic stem-cell transplantation-specific comorbidity index (HCT-CI) and the Charlson comorbidity index (CCI) were applied. Results: The HCT-CI was found to be a significant prognostic factor for overall survival (OS, P < 0.05) as well as event-free survival (EFS, P < 0.05) in our patients, whereas the CCI was of prognostic significance for OS (P < 0.05), but not for EFS. For AML-free survival, neither the HCT-CI nor the CCI were of predictive value. A multivariate analysis including age, lactate dehydrogenase, ferritin, karyotype, number of cytopenias, French-American-British groups, and comorbidity was applied. Comorbidity was found to be an independent prognostic factor in patients with low- or int-1-risk MDS (P < 0.05) regarding OS and EFS. Conclusions: Together, our data show that comorbidity is an important risk factor for OS and EFS in patients with MDS.

引用

页码：114 / 119

页数：6

共 40 条

[1] Impact of Acquired Comorbidities on All-Cause Mortality Rates Among Older Breast Cancer Survivors [J].

Ahern, Thomas P. ;

Lash, Timothy L. ;

Thwin, Soe Soe ;

Silliman, Rebecca A. .

MEDICAL CARE, 2009, 47 (01) :73-79

[2]

AUL C, 1994, LEUKEMIA, V8, P1906

[3]

AUL C, 1992, LEUKEMIA, V6, P52

[4] The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment [J].

Bennett, JM ;

Komrokji, RS .

HEMATOLOGY, 2005, 10 :258-269

[5] A comparative review of classification systems in myelodysplastic syndromes (MDS) [J].

Bennett, JM .

SEMINARS IN ONCOLOGY, 2005, 32 (04) :S3-S10

[6] THE CHRONIC MYELOID LEUKEMIAS - GUIDELINES FOR DISTINGUISHING CHRONIC GRANULOCYTIC, ATYPICAL CHRONIC MYELOID, AND CHRONIC MYELOMONOCYTIC LEUKEMIA - PROPOSALS BY THE FRENCH-AMERICAN-BRITISH-COOPERATIVE-LEUKEMIA-GROUP [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, H ;

SULTAN, C ;

COX, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (04) :746-754

[7]

BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[8] Treatment and prognostic factors in myelodysplastic syndromes [J].

Boogaerts, MA ;

Verhoef, GEG ;

Demuynck, H .

BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (01) :161-183

[9]

Brunning RD, 2001, WHO CLASSIFICATION T, P62

[10]

BRUNNING RD, 2008, WHO CLASSIFICATION T, V1, P88

← 1 2 3 4 →